STOCKHOLM, SWEDEN--(Marketwire - November 5, 2009) -

Biovitrum AB (publ) will hold a press conference today to present the proposed combination with Swedish Orphan International AB.

Time:               11:00 (CET), today Thursday November 5, 2009
Venue:             Carnegie's offices, Regeringsgatan 56 in
Stockholm, Sweden

To follow the press conference over telephone, please use the following dial-in number: + 46 (0) 850 520 270.

Conference call at 16:00 (CET)

A conference call for investors and media in other time zones will be held in English this afternoon at 16:00 (CET). Presentation materials will be available on our web site: www.biovitrum.com, where it also will be possible to listen to the conference call afterwards. The dial-in number for the telephone conference is + 46 (0) 850 520 270.

Welcome!

Erik Kinnman, EVP Investor Relations
Phone: +46 (0) 8 697 21 50, erik.kinnman@biovitrum.com

About Biovitrum

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit www.biovitrum.com

Invitation in PDF format: http://hugin.info/134557/R/1352888/327553.pdf

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.